Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

bluebird bio

Caterpillar

Cisco Systems

Chevron

Dow Inc

Erasca Inc

Intel

iShares Russell 2000 ETF

McDonald's

Walmart

Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative after the longest positive signal since March 2021 on the weekly gauges. Last week three of the four picks gained over the 10% mark, closing up an average of +9.17% for the week with strong Segment 6 momentum.

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

Salesforce

Form 13Fs provide investors with a snapshot of what Wall Street's brightest minds have been buying and selling. The iconic Dow Jones Industrial Average is comprised of 30 generally profitable, time-tested, multinational businesses.

3 Widely Owned Dow Stocks Prominent Billionaires Are Selling

D.R. Horton

DaVita

Kraft Heinz

Kroger

Occidental Petroleum

During times of market volatility, many investors look to see which stocks Warren Buffett is buying. Spoiler alert, you won't find him chasing the hottest AI stocks.

7 Very Oversold Warren Buffett Stocks to Buy Right Now

British American Tobacco

Coca-Cola

You know Johnson & Johnson as a consumer health company. But its exit from a major business is the top reason you'll want to own the stock when things get tough.

3 Stocks to Buy That Can Beat a Bear Market

Kenvue

Small investors earned a nice payday of more than $1,000 if they tendered 99 shares of stock in the swap, which expired last week.

J&J's Kenvue Exchange Offer Was a Big Win for the Little Guy

Ally Financial

Bank of America

Citigroup

Capital One

General Motors

Jefferies Financial Group Inc

Louisiana-Pacific

Paramount Global

This Buffett holdings list from Kiplinger first appeared 8/21/23 online. Kiplinger, YCharts and Dogs of The Dow all track this Buffett/Berkshire batch. Here is your update from 8/22/23 YCharts. 32 of 48 current Berkshire Hathaway-owned stocks pay dividends. As of 8/22/23, the top-ten ranged 2.87%-5.02% by annual yield and 45 of 48 ranged -0.16%-57.71% per broker-estimated target-price-upsides. Analyst-augured top-ten net gains from Buffett's August dividend dogs ranged 19.12%-56.48% from CVX, COF, DHI, LPX, KHC, BAC, PARA, ALLY, C, and top pick GM per YCharts data.

The Buffett List: 6 Dividend Buys In August

Costco

PepsiCo

Procter & Gamble

In the ever-changing landscape of financial markets, the search for stability and resilience remains a paramount concern, especially in the face of potential economic downturns. Ray Dalio (Trades, Portfolio), the visionary founder of Bridgewater Associates, is well-known for his strategic prowess in navigating market fluctuations.

Bridgewater's Approach: Stocks for an Upcoming Recession

Johnson & Johnson recently completed the Kenvue spinoff. We outline the impacts on its dividend payouts from this spinoff. I analyzed its dividend payout both using simple payout ratios and also using a more holistic approach such as the dividend cushion ratio.

Johnson & Johnson: Kenvue Separation Won't Impact Dividends

Atmos Energy

Entergy

McKesson

Volatility has gripped Wall Street again. So, investing in defensive stocks like McKesson Corporation (MCK), Entergy Corporation (ETR), PepsiCo, Inc. (PEP), Johnson & Johnson (JNJ) and Atmos Energy Corporation (ATO) is a safe bet.

5 Defensive Stocks to Buy Amid Lingering Market Volatility

Petco Health and Wellness

Autodesk

C3.ai

Bowlero Corp

Discover

Ford Motor Company

Martin Marietta Materials

Snowflake

Toll Brothers

Vulcan Materials

Walgreens

Williams-Sonoma

Here are some of the tickers on my radar for Thursday, Aug. 24, taken directly from my reporter's notebook.

Here are 16 stocks Jim Cramer is watching, including J&J split-off Kenvue, Petco, GM

Johnson & Johnson's Dutch business Janssen, which helped to develop the single-dose COVID-19 vaccine, will close almost its entire vaccine division, the company said on Wednesday, confirming Dutch media reports.

J&J's Janssen to close part of its vaccine division

Kenvue announced that Wednesday, August 23, marked its first day as a fully independent company after it completed its separation from Johnson & Johnson (NYSE:JNJ). The consumer health company, whose brands include Aveeno, Band-Aid, Listerine, Neutrogena, and Tylenol, was spun off from J&J earlier this year, debuting on the New York Stock Exchange on May 4 for $22 a share.

Kenvue completes separation from J&J ahead of S&P 500 inclusion

Johnson & Johnson investors were able to exchange less than a quarter of their shares for the consumer split off. The company will update financial guidance next week

J&J Makes it Official: Kenvue Stock Swap Offer Was a Huge Hit With Shareholders

Kenvue Inc. KVUE, +3.67% kicks off life as a fully independent public company Wednesday after completing its separation from Johnson & Johnson JNJ, -0.79%, the company said in a release. J&J accepted an aggregate of 191 million shares of its common stock in exchange for 1.53 billion shares of Kenvue's common stock and now owns 9.5% of Kenvue's outstanding shares.

Kenvue becomes ‘fully independent' after final separation from J&J

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Pursuant to the exchange offer, Johnson & Johnson has accepted 190,95.

Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.

J&J holders who participated in the exchange offer can choose which J&J shares they want to use for their cost basis in Kenvue.

J&J's Exchange Offer for Kenvue Is Tricky From a Tax Standpoint. What to Do.

News for Johnson & Johnson Stock (JNJ)